2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Surgical, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

6156 Cost-effectiveness of comprehensive genomic profiling-guided treatment selection in newly diagnosed large B-cell lymphoma

Dai Chihara, MD, PhD, James I Barnes, MD2, Navika Sonig3, Jeremy Young4, Christopher R. Flowers Jr, MD, MS5, John K Lin, MD, MSHP6
1 MD Anderson Cancer Center, Houston, Texas, United States
2 University of Washington, Seattle, United States
3 Rice University, Houston, Texas, United States
4 MD Anderson Cancer Center, Houston, United States
5 MD Anderson Cancer Center, Houston, Texas, United States
6 MD Anderson Cancer Center, Houston, United States

INTRODUCTION: Large B-cell lymphoma (LBCL) is a biologically heterogeneous disease with emerging molecular biomarkers that may predict response to frontline therapy. As multiple effective first-line treatment options become available, including bispecific antibodies, antibody-drug conjugates and immunomodulatory-based combinations, selecting the optimal therapy for an individual patient is becoming increasingly complex. Comprehensive genomic profiling (CGP) has the potential to improve treatment selection by accurately identifying biologically distinct subtypes; however, its economic value has not been established. We evaluated the cost-effectiveness of implementing rapid CGP at diagnosis to guide first-line treatment selection in LBCL.

METHODS: A semi-Markov model was developed from the US healthcare payer perspective to compare four first-line treatment strategies utilizing currently available standard-of-care regimens (R-CHOP, R-CHP-pola, and DA-EPOCH-R): (1) empiric R-CHOP for all patients, (2) empiric R-CHP-pola for all patients, (3) immunohistochemistry (IHC)-guided treatment, and (4) CGP-guided treatment incorporating cell-of-origin (COO) and dark zone signature (DZsig) classification. Patients with double-hit lymphoma received DA-EPOCH-R regardless of treatment strategy. In the IHC-guided strategy, patients with germinal center B-cell-like (GCB) disease received R-CHOP and patients with non-GCB disease received R-CHP-pola. In the CGP-guided strategy, patients with GCB subtype received R-CHOP, activated B-cell (ABC) subtype received R-CHP-pola, DZsig subtype received DA-EPOCH-R, and unclassified patients received R-CHOP. Transition probabilities were calibrated using published progression-free survival and overall survival data. Contemporary treatment pathways following relapse included salvage chemotherapy, autologous stem cell transplantation, lisocabtagene maraleucel, glofitamab, and other standard therapies according to timing of relapse. The cost of CGP was assumed to be $3,500 (2026 USD). Primary outcomes included discounted healthcare costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Costs and health outcomes were modeled over patients’ lifetimes and discounted at 3% annually. A willingness-to-pay threshold of $150,000/QALY was used.

RESULTS: The CGP-guided strategy produced the greatest health benefit among all modeled strategies, yielding 7.95 discounted QALYs. Compared with the IHC-guided strategy, CGP-guided treatment improved QALYs by 0.17 while reducing lifetime healthcare costs by $26,356, thereby dominating the IHC-guided strategy. Compared with empiric R-CHP-pola, CGP-guided treatment was also dominant, improving QALYs by 0.15 and reducing lifetime healthcare costs by $43,661. Compared with empiric R-CHOP, CGP-guided treatment improved QALYs by 0.85 at an incremental lifetime cost of $31,633, resulting in an ICER of $37,312/QALY, substantially below the accepted willingness-to-pay threshold. Results remained robust in one-way sensitivity analyses, including CGP costs up to at least $5,000. 

CONCLUSIONS: Implementation of comprehensive genomic profiling to guide first-line treatment selection in LBCL is projected to improve quality-adjusted survival while reducing overall healthcare costs compared with IHC-guided treatment and empiric R-CHP-pola strategies. Compared with empiric R-CHOP, CGP-guided treatment remained highly cost-effective. These findings suggest that comprehensive molecular characterization provides substantial clinical and economic value by enabling precision allocation of existing standard-of-care therapies and support prospective evaluation of CGP-guided treatment strategies in frontline LBCL.

Dai Chihara, MD, PhD: Chugai - Honoraria; Lyell - Research Funding; BMS - Research Funding; Genentech - Research Funding; Treeline - Research Funding; Genmab - Research Funding; Ono - Research Funding; REGENERON - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Miltenyi Biomedicine - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony)